Clinical trial
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
NCT00477087 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00477087 |
|---|---|
| Title | Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer |
| Official title | Phase II Study of Granulocyte-Macrophage Colony Stimulating Factor Plus Mitoxantrone for the Treatment of Hormone Refractory Prostate Cancer |
| Lead sponsor | Stanford University, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Mitoxantrone, GM-CSF |
| Enrollment | 10 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | May 22, 2007 |
| Last update posted | Nov 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: